Clinical Trials Browser

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT06184750 2026-03-19

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Phase 2 Recruiting

200 enrolled

Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT03941730 2026-03-05

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Phase 2 Active not recruiting

8 enrolled 9 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06860815 2026-01-28

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

Phase 2 Recruiting

11 enrolled

Breast

Breast Neoplasms

NCT01494662 2026-01-23

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Phase 2 Completed

140 enrolled 32 charts

Breast

Breast Neoplasms

NCT05557877 2026-01-06

Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer

Phase 2 Recruiting

100 enrolled

Breast

Breast Neoplasms

NCT02849496 2025-11-24

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Phase 2 Active not recruiting

81 enrolled

Breast

Breast Neoplasms

NCT01149083 2025-08-15

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Phase 2 Completed

77 enrolled 17 charts

Breast

Breast Neoplasms

NCT03272477 2024-04-17

TP-II

Phase 2 Completed

257 enrolled

Breast

Breast Neoplasms

NCT05619016 2022-11-30

[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors

Phase 2 Unknown

72 enrolled

BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms

NCT02997995 2020-09-30

ULTIMATE

Phase 2 Completed

61 enrolled

Breast

Breast Neoplasms

NCT01372579 2019-06-07

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

Phase 2 Unknown

30 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00847171 2018-09-26

Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer

Phase 2 Completed

20 enrolled 6 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00088829 2018-07-11

Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer

Phase 2 Terminated

22 enrolled 3 charts

Breast

Breast Neoplasms

NCT00201773 2015-06-30

Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer

Phase 2 Completed

22 enrolled 9 charts

Breast

Breast Neoplasms

NCT00343512 2012-04-27

Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer

Phase 2 Terminated

34 enrolled 9 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00645866 2011-05-16

Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer

Phase 2 Completed

47 enrolled

Breast

Breast Neoplasms

Clinical Trials

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

TP-II

[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors

ULTIMATE

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer

Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer

Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer

Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer

Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer